Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

This study is testing a CAR-T cell therapy for adults and teenagers with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) — a type of blood cancer that has come back or stopped responding to standard treatment. CAR-T therapy uses your own immune cells, which are collected, genetically engineered to target cancer cells, and then infused back into your body. **You may be eligible if...** - You have B-cell ALL that has relapsed (come back) or is not responding to treatment - You are between 13 and 65 years old - You have no detectable leukemia in the fluid around your brain and spinal cord - Your organs are functioning well enough to tolerate the treatment **You may NOT be eligible if...** - You have active leukemia spreading to the central nervous system - You have serious active infections or other cancers - You have severe organ problems (heart, liver, kidney, lungs) - You are pregnant or breastfeeding - You have previously received CAR-T therapy Talk to your doctor to see if this trial is right for you.